February 8, 2011

Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant Recipients

.   .   

This randomized-controlled study continues work being done to define the place of the co stimulatory blocker belatacept in renal transplantation. This trial compared three regimens of rapid corticosteroid withdrawal, two of which avoided calcineurin inhibitors by using belatacept. Rejection rates were low at one year, and renal function was better in patients on belatacept instead of tacrolimus.

Related Articles:

Renal Transplantation

Comments are closed.